Results 31 to 40 of about 33,038 (222)

Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Prostate cancer is the leading cause of cancer death among men globally, with castration development resistant contributing significantly to treatment failure and death.
Solomon Oladapo Rotimi, Oluwakemi Anuoluwapo Rotimi, Abdulkadir Ayo Salako, Paul Jibrin, Jelili Oyelade, Emeka E. J. Iweala   +5 more
doaj   +1 more source

Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer

SAGE Open Medicine, 2023
Objectives: To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer.
Gen Kawaguchi, Kohei Akazawa, Taro Ikeda, Yohei Ikeda, Noboru Hara, Tsutomu Nishiyama   +5 more
doaj   +1 more source

Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. [PDF]

PLoS ONE, 2012
The recently described transcriptomic switch to a mitosis program in castration-resistant prostate cancer (CRPC) suggests that mitotic proteins may be rationally targeted at this lethal stage of the disease.
Kanishka Sircar, Heng Huang, Limei Hu, Yuexin Liu, Jasreman Dhillon, David Cogdell, Armen Aprikian, Eleni Efstathiou, Nora Navone, Patricia Troncoso, Wei Zhang   +10 more
doaj   +1 more source

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2019
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.We conducted a randomized, double-blind, placebo-controlled, phase 3 trial ...
Fizazi, Karim, Shore, Neal, Tammela, Teuvo L, Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Kappeler, Christian, Snapir, Amir, Sarapohja, Toni, Smith, Matthew R, for the ARAMIS Investigators, Aglietta, Massimo, Damiano, Rocco, Facchini, Gaetano, Gasparro, Donatello, Mucciardi, Giuseppe, Natoli, Clara, Sabbatini, Roberto, Scagliotti, Giorgio, Schepisi, Giuseppe, Serretta ,Vincenzo   +24 more
openaire   +3 more sources

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy

Frontiers in Oncology, 2016
Historically, androgen-deprivation therapy was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer, there are a few life-prolonging drugs, including taxanes such as docetaxel
Masaki eShiota, Akira eYokomizo, Masatoshi eEto   +2 more
doaj   +1 more source

Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators

Asian Journal of Andrology, 2023
Prostate cancer is one of the most common diseases in men worldwide. Surgery, radiation therapy, and hormonal therapy are effective treatments for early-stage prostate cancer. However, the development of castration-resistant prostate cancer has increased
Sayuri Takahashi, Ichiro Takada
doaj   +1 more source

Aggressive Variants of Castration-Resistant Prostate Cancer [PDF]

Clinical Cancer Research, 2014
Abstract A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)–independent phenotype, with a clinical picture associated with the development of rapidly progressive disease involving visceral sites and hormone refractoriness, often in the setting of a low or modestly ...
Himisha, Beltran, Scott, Tomlins, Ana, Aparicio, Vivek, Arora, David, Rickman, Gustavo, Ayala, Jiaoti, Huang, Lawrence, True, Martin E, Gleave, Howard, Soule, Christopher, Logothetis, Mark A, Rubin   +11 more
openaire   +2 more sources

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. [PDF]

PLoS ONE, 2012
MicroRNAs (miRs) are small, endogenous, non-coding RNAs that regulate the stability and/or translation of complementary mRNA targets. MiRs have emerged not only as critical modulators of normal physiologic processes, but their deregulation may ...
Reema A Ishteiwy, Toby M Ward, Derek M Dykxhoorn, Kerry L Burnstein   +3 more
doaj   +1 more source